Drug Profile
SB 030
Alternative Names: SB-030; SBCV 030Latest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator SYMIC Biomedical
- Developer Symic Bio
- Class Proteoglycans; Vascular disorder therapies
- Mechanism of Action Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Transplant rejection
Most Recent Events
- 25 Apr 2019 Symic Bio plans a global phase III trial for Peripheral vein graft failure (Prevention) in 2020
- 02 Apr 2018 Symic Bio announces intention to submit IND to US FDA for a phase II trial in Transplant rejection (Prevention)
- 02 Apr 2018 Interim efficacy and adverse events data from the phase I/II SHIELD trial in Peripheral arterial disorders released by Symic Bio